<unk>  has been reported to bind to an assortment of molecular sites, including: μ-opioid (Ki = 2.0 μM), δ-opioid (Ki = 8.1 μM), and κ-opioid receptors (Ki = 4.3 μM), NMDA receptor (Ki = 6.24 μM) (as an antagonist), and nAChRs (as an antagonist). It has also been found to inhibit the enzyme acetylcholinesterase, act as a voltage-gated sodium channel blocker, and displays estrogenic activity in rodents. In contrast to ibogaine and other iboga alkaloids,<unk>  does not bind to either the σ1 or σ2 receptor.
Coronaridine
Nortilidine
Iofetamine 
Lofexidine
Adenosine
Ivabradine
Veratridine
Maprotiline